Cuál es el precio por Impel Pharmaceuticals Inc. (IMPL)

Precio por Impel Pharmaceuticals Inc. (IMPL) es de$0.1011

Cuál es la capitalización de mercado por Impel Pharmaceuticals Inc. (IMPL)

Capitalización de mercado por Impel Pharmaceuticals Inc. (IMPL) es $1.96M

Impel Pharmaceuticals Inc. (IMPL) Dividendos

Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.

Año	Dividendo (ajustado por splits de acciones)	Cambiar
Not enough data for the provided dates.

Año

Dividendo (ajustado por splits de acciones)

Cambiar

Not enough data for the provided dates.

Año	Dividendo	Cambiar
Not enough data for the provided dates.

Año

Dividendo

Cambiar

Not enough data for the provided dates.

Empresa	Número de pagos de dividendos	País
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

Empresa

Número de pagos de dividendos

País